Visx
This article was originally published in The Gray Sheet
Executive Summary
Ophthalmic laser firm will pay about $37.8 mil. to settle antitrust class action suits relating to its Pillar Point joint venture with competitor Summit Autonomous (1"The Gray Sheet" July 13, 1998, p. 15). Alcon Labs' Summit unit also has settled under separate arrangements. Pillar Point was deemed anti-competitive by FTC, which alleged the firms were preventing competitors from entering the laser vision correction market by failing to license patents
You may also be interested in...
Visx/Summit Enter FTC Consent Decrees On Pillar Point Partners Venture
Visx and Summit Technology have entered separate consent decree settlements with the Federal Trade Commission regarding their Pillar Point Partners joint venture, the two ophthalmic laser manufacturers announced July 8.
Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune
The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.